Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Top News
Top News
Health

Wegovy Approved To Reduce Cardiovascular Risk In Overweight Patients

This image provided by Novo Nordisk in January 2023, shows packaging for the company's Wegovy medication. The popular weight-loss drug, which has helped millions of Americans shed pounds, can n

The FDA has approved a label change for the weight-loss drug Wegovy, allowing it to be used to reduce the risk of stroke, heart attacks, and other serious cardiovascular problems in patients who are overweight or have obesity. This decision follows a study that showed Wegovy significantly decreased the risk of heart-related issues, including heart attack, stroke, and heart-related deaths.

The study found that higher-weight patients with heart disease but without diabetes were 20% less likely to experience these problems when taking Wegovy compared to those who received a placebo. This makes Wegovy the first medication approved to prevent such events in this population.

Dr. John Sharretts, from the FDA, stated that providing a treatment option proven to lower cardiovascular risk is a significant advancement for public health. Dr. Martha Gulati, a cardiologist, noted that this approval will change the way many heart patients are treated and emphasizes the health benefits of the new class of obesity medications.

Wegovy, a higher-dose version of Ozempic, typically costs around $1,300 a month. While the drug has shown promising results, it also carries risks of serious side effects, including thyroid tumors, certain cancers, low blood sugar, and other health issues.

The FDA cautioned that about a third of participants in the clinical trial reported serious side effects, with some discontinuing the study due to these effects. Despite the potential benefits, limited drug supply has been a challenge, with Novo Nordisk working to increase production.

The new indication for Wegovy could lead to increased coverage by Medicare, potentially allowing more individuals to access the drug. Private insurers will also evaluate coverage decisions based on the FDA's approval.

While drugmakers and obesity advocates have been advocating for expanded coverage, concerns remain about the cost-effectiveness of these medications and their impact on healthcare spending related to obesity and heart disease.

Overall, the approval of Wegovy for reducing cardiovascular risk in overweight patients marks a significant development in the treatment of obesity-related health issues, with potential implications for public health and insurance coverage.

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.